全文获取类型
收费全文 | 90篇 |
免费 | 6篇 |
专业分类
耳鼻咽喉 | 2篇 |
基础医学 | 16篇 |
口腔科学 | 4篇 |
临床医学 | 1篇 |
内科学 | 17篇 |
皮肤病学 | 1篇 |
神经病学 | 3篇 |
外科学 | 4篇 |
预防医学 | 2篇 |
眼科学 | 1篇 |
药学 | 36篇 |
肿瘤学 | 9篇 |
出版年
2022年 | 2篇 |
2021年 | 2篇 |
2020年 | 2篇 |
2019年 | 1篇 |
2018年 | 5篇 |
2017年 | 2篇 |
2016年 | 4篇 |
2015年 | 2篇 |
2014年 | 5篇 |
2013年 | 10篇 |
2012年 | 5篇 |
2011年 | 7篇 |
2010年 | 3篇 |
2009年 | 5篇 |
2008年 | 6篇 |
2007年 | 8篇 |
2006年 | 5篇 |
2005年 | 4篇 |
2003年 | 1篇 |
2002年 | 1篇 |
1991年 | 2篇 |
1989年 | 1篇 |
1988年 | 1篇 |
1987年 | 1篇 |
1986年 | 1篇 |
1985年 | 1篇 |
1984年 | 1篇 |
1983年 | 3篇 |
1980年 | 1篇 |
1979年 | 2篇 |
1977年 | 2篇 |
排序方式: 共有96条查询结果,搜索用时 0 毫秒
81.
82.
83.
84.
85.
Gevorgyan A Yaghjyan GV Shamakhyan HV Danielyan AM Sahakyan AB 《The Journal of craniofacial surgery》2008,19(2):513-516
The frontalis musculocutaneous island flap offers advantages of immediate repair for small to medium-sized forehead defects (0.5-5 x 0.5-5 cm). Based on the supraorbital artery, the flap is both adaptable and dependable. Advantages of this flap include the ability to perform the procedure immediately and in one stage, rapid aesthetic restoration, minor donor-site morbidity, and technical ease. A clinical report demonstrating the use of this flap for repair of an electrothermal injury to the glabella is presented. 相似文献
86.
Clinical update on palonosetron in the management of chemotherapy-induced nausea and vomiting 总被引:1,自引:0,他引:1
The need to control chemotherapy-induced nausea and vomiting is continuously stimulating research to find better options for the optimal antiemetic care. Palonosetron is different from conventional serotonin receptor antagonists not only by the fact of having a longer half-life but also by higher binding affinity for serotonin receptors. It is the first agent in the class which is approved for preventing both delayed and acute emesis induced by moderately emetogenic chemotherapy. Recent studies using palonosetron-based antiemetic regimens, as well as in the clinical setting of multiple-day chemotherapy, have been reported. Palonosetron plus dexamethasone given as a pre-treatment infusion was effective for preventing acute and delayed emesis after moderately emetogenic chemotherapy. Palonosetron in combination with dexamethasone and aprepitant was highly effective in preventing emesis in the days following administration of moderately emetogenic chemotherapy. Treatment was well tolerated, with no unexpected adverse events. Multiple-day dosing of palonosetron plus dexamethasone was safe and effective for prevention of emesis induced by 5-day cisplatin-based chemotherapy. There was no evidence of cumulative toxicity when palonosetron was given three times over 5 days. Further evidence from ongoing clinical trials with palonosetron with or without dexamethasone will be available soon. Palonosetron represents an useful addition to the therapeutic armamentarium for the management of chemotherapy-induced nausea and vomiting. Further studies are needed to assess the effectiveness of palonosetron in combination with dexamethasone compared with that of older serotonin receptor antagonists combined with dexamethasone. However, palonosetron may offer advantages of convenience over the short-acting older antagonists due to its ability to be given as a single intravenous dose prior to chemotherapy. 相似文献
87.
88.
89.